Furthermore, Vitrolife will record a goodwill impairment of SEK 5.4 billion in Q4 2025, related to the Igenomix acquisition, it states.

Discontinue two genetic test lines

As part of the restructuring program, Vitrolife has decided to discontinue two genetic test lines (GPDx and NACE). An agreement has been reached with Unilabs to ensure continued access to these genetic services for selected customers. Vitrolife will in addition exit low profit markets within the genetic services business to concentrate on tests and markets that offer profitable growth potential. Together, GPDx, NACE and low-profit markets account for approximately 2-3% of the Group’s revenue.

Impact approximately 6% of Vitrolife’s workforce

The restructuring program will impact approximately 6% of Vitrolife’s workforce incurring restructuring costs of SEK 55 million which will be recorded in the fourth quarter of 2025.

“Over the past two years, we have successfully brought the genetic services business to growth and improved profitability. With today’s decisions we will increase focus and lay the foundation for further improvements in the financial performance of genetic services,” says Bronwyn Brophy O’Connor, CEO of the Vitrolife Group.